NCT06241742

Evaluating Ability of HT-6184 to Reduce Inflammation and Pain After Third Molar Extraction

A Phase-2 Study to Evaluate the Ability of HT-6184 to Attenuate Diagnostic Biomarkers of Post-procedure Acute Inflammation and Manage Pain Following Third Molar Extraction

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 81 (actual)
• Sponsor: Halia Therapeutics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

The goal of this clinical trial is to test the ability of HT-6184 to decrease inflammation and pain in patients after third molar removal. The main question it aims to answer are: * Does HT-6184 decrease inflammation in patients after third molar removal? * Does HT-6184 decrease pain in patients after third molar removal? Participants will be asked to do the following during the clinical trial: * Take a single oral dose of HT-6184 or placebo * Allow a oral surgeon remove their third molar teeth * Blood draws on 5 occurrences * Rate their pain intensity * Attend two follow-up appointments on day 1 and day 2 after third molar removal * Participate in one follow-up phone call 5-7 days after third molar removal

Conditions

• Pain

Interventions

Type	Name	Description
DRUG	HT-6184	Single, oral dose of HT-6184
DRUG	HT-6184 Placebo	Single, oral dose of placebo

Timeline

• Start date: 2024-02-12
• Primary completion: 2024-04-30
• Completion: 2024-04-30
• First posted: 2024-02-05
• Last updated: 2025-03-30

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study